Benign gynecological diseases and SERMs

Stefano Palomba, Fulvio Zullo

Research output: Chapter in Book/Report/Conference proceedingChapter


At present, the only SERMs routinely used in clinical practice are tamoxifen and raloxifene. Tamoxifen is used essentially as adjuvant treatment in women with breast cancer. Its use is related to estrogenic effects on the uterus. Specifically, tamoxifen can be associated with an increase not only in endometrial hyperplasia and cancer risk but also in uterine leiomyoma dimensions and in a risk of developing active endometriotic lesions. Raloxifene is actually used for the treatment and prevention of post-menopausal osteoporosis. Also, if raloxifene has been shown to have any effect on uterine leiomyomas in vitro and in animal models, to date no concrete efficacy has been demonstrated in normally cycled premenopausal women. Moreover, the addition of raloxifene to GnRH-a administration can be useful for limiting GnRH-a-related side effects and increasing the rate of reduction in tumor size. Regarding the use of SERMs in women with endometriosis, the efficacy of raloxifene or other compounds is only potential. Experimental studies to determine if SERMs have a greater potency against uterine leiomyomas and endometriosis are currently in progress.

Original languageEnglish
Title of host publicationSelective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs
PublisherSpringer Berlin Heidelberg
Number of pages21
ISBN (Print)3540242279, 9783540242277
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Benign gynecological diseases and SERMs'. Together they form a unique fingerprint.

Cite this